M2613 Explained

M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.[1] [2]

See also

Notes and References

  1. Walpole AL, Paterson E . Synthetic oestrogens in mammary cancer . Lancet . 2 . 6583 . 783–6 . October 1949 . 15391512 . 10.1016/s0140-6736(49)91370-7 .
  2. Jordan VC . The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer . Endocr. Relat. Cancer . 22 . 1 . R1–31 . February 2015 . 25339261 . 4494663 . 10.1530/ERC-14-0448 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "M2613".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.